Civitas Therapeutics Announces Positive Phase 2 Clinical Results for CVT-301
4/19/2013 10:32:41 AM
More...
|
Civitas Therapeutics to Present Positive Clinical Study Results for CVT-301 at Sixth Annual Parkinson’s Disease Therapeutics Conference, Sponsored by The Michael J. Fox Foundation for Parkinson’s Research
10/15/2012 10:21:27 AM
More...
|
Civitas Therapeutics to Present Positive Clinical Study Results for CVT-301 at Sixth Annual Parkinson's Disease Therapeutics Conference, Sponsored by The Michael J. Fox Foundation for Parkinson's Research
10/15/2012 10:02:16 AM
More...
|
Civitas Therapeutics Appoints Bryan E. Stuart Chief Business Officer
9/5/2012 9:53:09 AM
More...
|
Civitas Therapeutics Initiates Phase 2a Clinical Study of CVT-301, an Inhaled L-dopa for Parkinson's Disease
6/15/2012 9:13:12 AM
More...
|
Civitas Therapeutics Announces Positive Results from Clinical Study of CVT-301, an Inhaled L-dopa for Parkinson's Disease
1/6/2012 7:26:59 AM
More...
|
Civitas Therapeutics Announces Award of The Michael J. Fox Foundation Grant and Lead Drug Candidate for Parkinson's Disease
11/29/2011 9:33:27 AM
More...
|